English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

Background The use of inactivated autologous HIV-1 from infected patients as an antigen formulation for a therapeutic vaccine involves the isolation and propagation of HIV in cellculture conditions fulfilling the clinical grade Good Manufacturing Practice (GMP), and the development of analysis systems to detect adventitious agents. In this study we present the development of heat inactivated autologous HIV-1 produced Ex vivo to be used as immunogen in human therapeutic vaccine (Clinical Trial DCV02).

P18-07. Ex vivo production of autologous HIV-1 to be used as immunogen in autologous dendritic cell-based therapeutic vaccine (clinical trial DCV02)